
Rupesh Rastogi
I have done M. Sc. (Env Sci), P.G.D.E.P. L, LL.B from Lucknow University and M.B.A form Institute of Engineering and Technology Lucknow. I did Ph.D on the topic “Impact of process patent regime to product patent regime on Indian Pharmaceutical Industry. I have more than 16 years of academic and corporate experience. My areas of interest are Patent Laws, Indian Pharmaceutical Industry,Business Laws, Supply Chain Management, Human Resource Management, Environment and Sustainable Development . I have has published a number of research papers.
Phone: +91-9236097162
Phone: +91-9236097162
less
Related Authors
Neeti Singh
Maharaja Sayajirao University of Baroda
Scott R. Stroud
The University of Texas at Austin
Lawrence Liang
Ambedkar University Delhi
Gourishwar Choudhuri
Maulana Azad College, Kolkata
Dr Mahesha V
Karnataka State Open University
SHANIMON SALEEM
University of Kerala
Dr. Desh Raj Sirswal
Panjab University, Chandigarh(India)
Sumit Kataria
University of Delhi
InterestsView All (6)
Uploads
Papers by Rupesh Rastogi
patent of drug molecule appeared in The Patents and Designs Act 1911. This patent protection led to very high medicine prices and
dominance of multinational pharmaceutical companies in India. To encourage the domestic pharmaceutical industry and to ensure
availability of cheap medicines to Indian citizens the Patent Act 1970 was enacted. The act made provision for process patents for
pharmaceuticals and agro-chemical products. This Act paved way for exponential growth of Indian pharmaceutical which became world
leader in the manufacture of generics. India signed the TRIPS Agreement in April 1994. At that point in time, India’s existing enactment of
the Patent Act of 1970 directly contravened Article 27 of the TRIPS Agreement. To comply with this article product patent was reintroduced
in India. This changed the level playing field for Indian pharmaceutical companies which were earlier spending a dismal percentage of total
sales on R&D activities are now spending significant amount on R&D activities. Pattern of ‘R&D’ by Indian pharmaceutical companies has
also changed. Earlier the Indian pharmaceutical companies were taking process patents but now are taking product patents.
The present paper is an attempt to assess the R&D activities of Indian pharmaceutical companies in changed legal scenario. Data from
various secondary sources has been taken and suitably analyzed to achieve a detailed account of R&D activities of Indian pharmaceutical
companies in pre and post TRIPS period. The paper provides an insight to Indian pharmaceutical industry.
The DEA tool assists the administrators to identify the inefficient measures and take necessary actions for improvement. The results are indicative of the scenario that changed patent laws in India are not detrimental to the financial and overall health of Indian pharmaceutical companies in general. The Indian pharmaceutical companies have suitably modified their business model to cope up with the changed legal environment. It is a positive sign for all Indian pharmaceutical
companies that they are dynamic in management and operational policies to face any new situation and shall flourish more in the coming days.
patent of drug molecule appeared in The Patents and Designs Act 1911. This patent protection led to very high medicine prices and
dominance of multinational pharmaceutical companies in India. To encourage the domestic pharmaceutical industry and to ensure
availability of cheap medicines to Indian citizens the Patent Act 1970 was enacted. The act made provision for process patents for
pharmaceuticals and agro-chemical products. This Act paved way for exponential growth of Indian pharmaceutical which became world
leader in the manufacture of generics. India signed the TRIPS Agreement in April 1994. At that point in time, India’s existing enactment of
the Patent Act of 1970 directly contravened Article 27 of the TRIPS Agreement. To comply with this article product patent was reintroduced
in India. This changed the level playing field for Indian pharmaceutical companies which were earlier spending a dismal percentage of total
sales on R&D activities are now spending significant amount on R&D activities. Pattern of ‘R&D’ by Indian pharmaceutical companies has
also changed. Earlier the Indian pharmaceutical companies were taking process patents but now are taking product patents.
The present paper is an attempt to assess the R&D activities of Indian pharmaceutical companies in changed legal scenario. Data from
various secondary sources has been taken and suitably analyzed to achieve a detailed account of R&D activities of Indian pharmaceutical
companies in pre and post TRIPS period. The paper provides an insight to Indian pharmaceutical industry.
The DEA tool assists the administrators to identify the inefficient measures and take necessary actions for improvement. The results are indicative of the scenario that changed patent laws in India are not detrimental to the financial and overall health of Indian pharmaceutical companies in general. The Indian pharmaceutical companies have suitably modified their business model to cope up with the changed legal environment. It is a positive sign for all Indian pharmaceutical
companies that they are dynamic in management and operational policies to face any new situation and shall flourish more in the coming days.